NEW YORK— HTG Molecular Diagnostics reported after the close of the market on Tuesday that its first quarter revenues dropped 66 percent year over year.
For the three months ended June 30, the Tucson, Arizona-based firm reported revenues of $2.0 million compared to $5.8 million in the same period the year before, beating the Wall Street estimate of $1.8 million. The firm attributed the decrease to the impact of the COVID-19 pandemic, which required the closure of customer facilities around the globe during the quarter.